BRUCKNER GROUP - Key Persons
David Balekdjian is the CEO and Co-Founder of The Bruckner Group. For over twenty years, David has led and worked on assignments involving every aspect of drug and device development and commercialization, from early-stage clinical trials through FDA approval, commercialization strategy, healthcare value strategy, payer strategy, business development/corporate partnering, marketing, and finance. Under David's leadership, Bruckner has become an industry pioneer and thought leader in healthcare value and payer strategy. David and his co-founders have developed substantial intellectual property solving complex clinical development and healthcare value problems. Clients and payers consistently confirm this IP produces results others are not achieving.
Michael Russo is President and Co-Founder of The Bruckner Group. With over 20 years of experience across nearly all aspects of healthcare therapy development, Michael bridges the scientific, medical, and business worlds of healthcare and possesses a combination of skill sets that puts him at the leading edge of pharma and biotech strategy development. Michael leverages his scientific and medical expertise to help biopharmaceutical and medical device companies solve complex business problems at the intersection of science, medicine, and the market. He regularly collaborates with executives to determine which assets they should prioritize and helps define the optimized clinical pathway for developing new therapeutics that maximizes chances for FDA approval and payer access. In addition to a broad range of pharma and biotech clients, Michael advises financial institutions and has previously worked with Fidelity Investments, the Cowen Group, and Merrill Lynch in assessing the future potential of healthcare products and companies.